Auricular vagus nerve stimulation drives analgesia via an auricle-brain axis in a mouse model of neuropathic pain.
Summary
In mice, taVNS applied to the auricular concha activates a defined JNG→NTS (POMC)→vlPAG circuit to produce analgesia. Optogenetic activation at multiple nodes recapitulates the effect, while chemogenetic silencing abolishes it, establishing a mechanistic substrate for taVNS-driven pain relief.
Key Findings
- taVNS of the auricular concha induces robust analgesia in a neuropathic pain mouse model.
- An auricle-to-brain circuit JNG→NTS (pro-opiomelanocortinergic neurons)→vlPAG mediates the effect.
- Optogenetic activation of central vagus terminals, JNG fibers, or NTS→vlPAG neurons mimics taVNS analgesia; chemogenetic silencing at these nodes abolishes it.
Clinical Implications
While preclinical, these findings support translational trials of taVNS for perioperative and chronic pain, inform electrode placement and dosing paradigms, and suggest biomarkers (e.g., brainstem-PAG engagement) to guide responder selection.
Why It Matters
This study provides first-in-class circuit-level evidence for how taVNS drives analgesia, a key step toward rational parameter optimization and indication targeting. It bridges peripheral auricular input to central pain-modulating structures.
Limitations
- Findings are in mice; human generalizability and optimal stimulation parameters remain to be established.
- No direct behavioral or physiological biomarkers for clinical responder stratification were tested.
Future Directions
Early-phase human studies should test taVNS parameter sets guided by this circuit, develop imaging/EEG biomarkers of NTS–PAG engagement, and evaluate analgesic efficacy in perioperative and chronic neuropathic pain populations.
Study Information
- Study Type
- Basic/Mechanistic
- Research Domain
- Pathophysiology
- Evidence Level
- V - Preclinical mechanistic evidence in a mouse model; no direct human outcomes.
- Study Design
- OTHER